ORPHA:2330
Kasabach-Merritt phenomenon
Also known as: Haemangioma-thrombocytopenia syndrome · Hemangioma-thrombocytopenia syndrome
Publications
1,782
Trials
5
Interventional, condition-specific
Researchers
1,203
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare hemorrhagic disorder characterized by potentially life-threatening thrombocytopenia, microangiopathic hemolytic anemia, and consumptive coagulopathy in the context of kaposiform hemangioendothelioma or tufted angioma.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007708
- MeSH:D059885
- OMIM:141000
- UMLS:C0221025
- NCIT:C3821
Additional Mondo synonyms (9)
Kasabach Merritt phenomenon · Kasabach Merritt syndrome · Kasabach-Merritt Phenomenon · Kasabach-Merritt syndrome · hemangioma-hemorrhage syndrome · hemangioma-thrombocytopenia syndrome · hemangiomatosis with thrombocytopenia · thrombocytopenia-hemangioma syndrome · thrombopenia-hemangioma syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,782 matched papers (892 in last 10 years) Source
- Phenotype characterisedPresent
28 HPO annotations (e.g. Hemangioma; Thrombocytopenia; Hypofibrinogenemia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
5 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
28
Associated phenotypes · MONDO:0007708
- Hemangioma
- Thrombocytopenia
- Hypofibrinogenemia
- Petechiae
- Purpura
Showing 5 of 28 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,782
1,782 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,782 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
892 in the last 10 years · low confidence
Phrase hits: 1,782 · MeSH hits: 0
Who's working on it?
1,203
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ji Y12 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 02Zhou J8 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 03Li K7 papers · 2026
Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
Papers in Europe PMC - 04Wang Y7 papers · 2026
Department of Neonatology, Anhui Provincial Children's Hospital, Anhui Medical University, Hefei, China.
Papers in Europe PMC - 05Zhang Y7 papers · 2026
Department of Pediatric Surgery, Chengdu Women and Children's Central Hospital, Chengdu, China.
Papers in Europe PMC - 06Gong X6 papers · 2025
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 07Lan Y6 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 08Qiu T6 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 09Wang Z6 papers · 2026
Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
Papers in Europe PMC - 10Yao W6 papers · 2025
Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
5
interventional trials for this specific condition
5 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
5 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 89.2th percentile).
low confidence · 89.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
5 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07656909·RECRUITING·Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Not reviewed·Conditions: Kaposiform Hemangioendothelioma (KHE) · Kasabach Merritt Phenomenon·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Kasabach-Merritt phenomenon — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Kasabach-Merritt phenomenon" OR "Haemangioma-thrombocytopenia syndrome" OR "Hemangioma-thrombocytopenia syndrome" OR "Kasabach Merritt phenomenon" OR "Kasabach Merritt syndrome" OR "Kasabach-Merritt syndrome" OR "hemangioma-hemorrhage syndrome" OR "hemangiomatosis with thrombocytopenia" OR "thrombocytopenia-hemangioma syndrome" OR "thrombopenia-hemangioma syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Kasabach-Merritt phenomenon" OR "Haemangioma-thrombocytopenia syndrome" OR "Hemangioma-thrombocytopenia syndrome" OR "Kasabach Merritt phenomenon" OR "Kasabach Merritt syndrome" OR "Kasabach-Merritt syndrome" OR "hemangioma-hemorrhage syndrome" OR "hemangiomatosis with thrombocytopenia" OR "thrombocytopenia-hemangioma syndrome" OR "thrombopenia-hemangioma syndrome"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 5 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1782) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T19:52:51.451Z
